

Supplemental Table 1	Austria	Belgium	France	Germany	Netherlands	Poland	Switzerland
Outcome							
ICU mortality	29 (28)	22 (14)	302 (31)	86 (17)	105 (17)	301 (48)	17 (10)
30-day-mortality	41 (43)	40 (28)	387 (40)	136 (29)	186 (33)	336 (57)	35 (21)
Treatment limitation							
Treatment withhold	38 (37)	46 (29)	374 (38)	73 (14)	297 (49)	103 (16)	66 (39)
Treatment withdraw	13 (13)	18 (11)	166 (17)	58 (11)	107 (18)	35 (6)	18 (11)
Management strategies							
NIV n (%)	43 (41)	21 (13)	341 (35)	162 (32)	65 (11)	64 (10)	59 (35)
Mechanical ventilation n (%)	36 (34)	53 (34)	491 (50)	238 (47)	270 (45)	560 (87)	58 (35)
Vasoactive drugs n (%)	47 (45)	66 (42)	454 (46)	323 (63)	337 (56)	519 (81)	73 (44)
Renal replacement therapy n (%)	15 (15)	7 (4)	110 (11)	87 (17)	24 (4)	145 (23)	9 (5)

### Supplemental Table 1

Primary and secondary outcomes for the specific countries in SHI.

Supplemental Table 2	Denmark	Spain	Greece	Ireland	Italy	Norway	Portugal	Sweden	UK
Outcome									
ICU mortality	52 (19)	73 (14)	155 (40)	38 (20)	279 (28)	81 (18)	105 (26)	102 (19)	382 (20)
30-day-mortality	104 (39)	124 (24)	184 (50)	61 (33)	375 (49)	181 (39)	151 (40)	221 (41)	567 (31)
Treatment limitation									
Treatment withhold	132 (49)	116 (22)	36 (9)	47 (25)	106 (11)	190 (41)	76 (19)	271 (51)	325 (17)
Treatment withdraw	32 (12)	52 (10)	11 (3)	32 (17)	106 (11)	83 (18)	52 (13)	101 (19)	284 (15)
Management strategies									
NIV n (%)	92 (34)	97 (18)	45 (12)	42 (22)	173 (18)	168 (36)	80 (20)	157 (29)	409 (22)
Mechanical ventilation n (%)	111 (41)	201 (38)	342 (88)	123 (64)	709 (72)	138 (30)	230 (57)	225 (42)	655 (35)
Vasoactive drugs n (%)	163 (60)	224 (42)	335 (86)	142 (74)	409 (41)	286 (62)	216 (54)	332 (62)	987 (52)
Renal replacement therapy n (%)	12 (5)	30 (6)	68 (18)	46 (24)	55 (6)	24 (5)	57 (14)	23 (4)	163 (9)

### Supplemental Table 2

Primary and secondary outcomes for the specific countries in THS.